The estimated prevalence of atrial fibrillation (AF) in the general population is about 1–4% and rises according to aging [1]. Cardiovascular comorbidities are utmost prevalent in patients with AF, as shown by data from the prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) registry, in which the prevalence of arterial hypertension, diabetes and hypercholesterolaemia was about 79.7%, 21.3% and 46.3%, respectively [2].
